The online version of this article (doi:10.1186/ar3394) contains supplementary material, which is available to authorized users.
AH is employed by Smith & Nephew and holds stocks and shares in Smith & Nephew. The Institute of Physiology, University Hospital Jena, was contracted by Smith & Nephew to conduct this study. Test substances were supplied and the Institute received funding from the company. However, no salary was paid to any of the authors employed by the University Hospital Jena.
MKB designed the study, took responsibility for animal healthcare, carried out part of the experiments, took care of the unblinding procedure, performed the statistical analysis, interpreted the data and wrote the manuscript. DK carried out parts of the experiments and statistical analysis. AH initiated the study, provided knowledge on the HA preparations and their clinical use, designed the study, and contributed to the manuscript. HGS designed the study, interpreted the data, and wrote the manuscript. All authors read and approved the final manuscript.
Clinical trials provided controversial results on whether the injection of hyaluronan preparations into osteoarthritic joints reduces pain. Problems of clinical studies may be the substantial placebo effects of intra-articular injections, different severity and rate of progression of the disease and others. We hypothesize that the use of preclinical pain models may help to clarify whether a certain hyaluronan exerts antinociceptive effects upon intra-articular injection. In the present study we tested in the bradykinin/prostaglandin E2 (PGE2) model primarily the putative antinociceptive effect of stabilized hyaluronic acid from a non animal source (NASHA), a stabilized hyaluronic acid based gel for intra-articular treatment of OA. We established a dose-response relationship for NASHA and we compared NASHA to other hyaluronans with different formulations that are in clinical use.
To induce transient joint pain episodes bradykinin and PGE2 were repetitively administered intra-articularly and unilaterally into rat knee joints during short anaesthesia. After establishment of the predrug nociceptive responses, a single intra-articular injection of saline or NASHA at different concentrations was administered and pain responses to further bradykinin/PGE2 injections were monitored up to 56 days after NASHA. Furthermore, the obtained effective dose was compared to clinically defined concentrations of Hylan GF20 and sodium hyaluronate. The primary outcome measures were primary mechanical hyperalgesia at the knee joint and pain-induced weight bearing.
On day 1 after injection, all tested hyaluronan preparations showed an antinociceptive effect >50% compared to saline. Single injections of higher doses of NASHA (50, 75 and 100 μl) were antinociceptive up to 56 days. When injection volumes in rat knee joints were adapted to clinical injection volumes in humans, the antinociceptive effects of the cross-linked NASHA and Hylan GF20 had a longer duration than that of the non cross-linked sodium hyaluronate (with a slightly better effect of NASHA than Hylan GF20).
In the bradykinin/PGE2 model of joint pain a single injection of all hyaluronan preparations provided significant antinociceptive effects compared to saline. It appeared that the duration of the antinociceptive effect of the cross-linked hyaluronan preparations NASHA and Hylan GF20 was more prolonged. In addition, the gel beads structure allowing only a slow release of hyaluronic acid (NASHA) may even enhance this prolonged antinociceptive effect.
Chevalier X, Jerosch J, Goupille P, van Dijk N, Luyten FP, Scott DL, Bailleul F, Pavelka K: Single, intraarticular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010, 69: 113-119. 10.1136/ard.2008.094623. PubMedCentralCrossRefPubMed
Neustadt DH: Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol. 2003, 21: 307-311. PubMed
Jorgensen A, Stengaard-Pedersen K, Simonsen O, Pfeiffer-Jensen M, Eriksen C, Bliddal H, Pedersen NW, Bodtker S, Horslev-Peteren K, Snerum LO, Egund N, Frimer-Larsen H: Intra-articular hyaluronan is without clinical effect in knee osteoarthritis a multicentre, randomised, placebo-controlled, double-bling study of 337 patients followed for 1 year. Ann Rheum Dis. 2010, 69: 1097-1102. CrossRefPubMed
Bellamy N, Campbell J, Robinson V, Gee T, Boume R, Wells GA: Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2005, 18: CD005328-
Auer JA, Fackelman GE, Gingerich DA, Fetter AW: Effect of hyaluronic acid in naturally occurring and experimentally induced osteoarthritis. Am J Vet Res. 1980, 41: 568-574. PubMed
Gingerich DA, Auer JA, Fackelman GE: Effect of exogenous hyaluronic acid on joint function in experimentally induced equine osteoarthritis: dosage titration studies. Res Vet Sci. 1981, 30: 192-197. PubMed
Gomis A, Miralles A, Schmidt RF, Belmonte C: Intra-articular injections of hyaluronan solutions of different elastoviscosity reduce nociceptive nerve activity in a model of osteoarthritic knee joint of the guinea pig. Osteoarthritis Cartilage. 2009, 17: 798-804. 10.1016/j.joca.2008.11.013. CrossRefPubMed
Schaible HG: Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol. 2007, 3-28.
Edsman K, Melin H, Näsström J: A study of the ability of Durolane™ to withstand degradation by free radicals while maintaining its viscoelastic properties. 55th Annual Meeting of the Orthopedic Research Society. 2009, Las Vegas: Congress Program; Itinerary Planner, 104: 1149-
Rice AS, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I, Preclinical Pain Consortium, Mogil JS, Stöhr T: Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain. 2008, 139: 243-247. 10.1016/j.pain.2008.08.017. CrossRefPubMed
Omata T, Segawa Y, Itokazu Y, Inoue N, Tanaka Y: Effects of chondroitin sulfate-C on bradykinin-induced proteoglycan depletion in rats. Arzneimittelforschung. 1999, 49: 577-581. PubMed
Davis AJ, Kelly D, Perkins MN: The induction of des-Arg9-bradykinin-mediated hyperalgesia in the rat by inflammatory stimuli. Braz J Med Biol Res. 1994, 27: 1793-1802. PubMed
Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Maiorino M, Pietra C, Rondelli I, Chamiot-Clerc P, Simonato M, Barbieri M: Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003, 306: 804-814. 10.1124/jpet.103.050039. CrossRefPubMed
Boettger MK, Hensellek S, Richter F, Gajda M, Stöckigt R, Segond von Banchet G, Bräuer R, Schaible HG: Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum. 2008, 58: 2368-2378. 10.1002/art.23608. CrossRefPubMed
Neugebauer V, Lucke T, Schaible HG: N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists block the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat's knee joint. J Neurophysiol. 1993, 70: 1365-1377. PubMed
Larsen NE, Dursema H, Skrabut EM: Clearance kinetics of a single injection crosslinked hylan-based viscosupplement in a rabbit model. Osteoarthritis Cartilage. 2007, 15 (Supplement): C64- CrossRef
- Evaluation of long-term antinociceptive properties of stabilized hyaluronic acid preparation (NASHA) in an animal model of repetitive joint pain
Michael Karl Boettger
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II